Search: onr:"swepub:oai:DiVA.org:uu-512688" >
Dapagliflozin in HF...
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists : An Analysis of DAPA-HF.
-
Shen, Li (author)
-
Kristensen, Soren Lund (author)
-
Bengtsson, Olof (author)
-
show more...
-
Bohm, Michael (author)
-
de Boer, Rudolf A. (author)
-
Docherty, Kieran F. (author)
-
Inzucchi, Silvio E. (author)
-
Katova, Tzvetana (author)
-
Kober, Lars (author)
-
Kosiborod, Mikhail N. (author)
-
Langkilde, Anna Maria (author)
-
Lindholm, Daniel (author)
-
Martinez, M. Felipe A. (author)
-
O’Meara, Eileen (author)
-
Nicolau, Jose C. (author)
-
Petrie, Mark C. (author)
-
Ponikowski, Piotr (author)
-
Sabatine, Marc S. (author)
-
Schou, Morten (author)
-
Sjostrand, Mikaela (author)
-
Solomon, Scott D. (author)
-
Jhund, Pardeep S. (author)
-
McMurray, John J. V. (author)
-
show less...
- Elsevier BV, 2021
- 2021
- English.
-
In: JACC. Heart failure. - : Elsevier BV. - 2213-1779. ; 9:4, s. 254-264
- Related links:
-
https://pure.rug.nl/...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVES: The purpose of this study was to assess the efficacy and safety of dapagliflozin in patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial. BACKGROUND: MRAs and sodium glucose co-transporter 2 inhibitors each have diuretic activity, lower blood pressure, and reduce glomerular filtration rate (GFR). Therefore, it is important to investigate the safety, as well as efficacy, of their combination. METHODS: A total of 4,744 patients with heart failure with reduced ejection fraction (HFrEF) were randomized to placebo or dapagliflozin 10 mg daily. The efficacy of dapagliflozin on the primary composite outcome (cardiovascular death or episode of worsening heart failure) and its components was examined according to MRA use, as were predefined safety outcomes. RESULTS: A total of 3,370 patients (71%) were treated with an MRA and they were younger (65 vs. 69 years of age), less often from North America (9% vs. 26%), had worse New York Heart Association functional class (35% vs. 25% in class III/IV), lower left ventricular ejection fraction (30.7% vs. 31.9%) and systolic blood pressure (120.3 vs. 125.5 mm Hg), but higher estimated GFR (67.1 vs. 62.6 ml/min/1.73 m(2)), than patients not taking an MRA. The benefit of dapagliflozin compared with placebo was similar in patients taking or not taking an MRA: hazard ratio: 0.74 (95% confidence interval [CI]: 0.63 to 0.87) versus 0.74 (95% CI: 0.57 to 0.95), respectively, for the primary endpoint (p value for interaction = 0.97); similar findings were observed for secondary endpoints. In both MRA subgroups, safety outcomes were similar in patients randomized to dapagliflozin or placebo. CONCLUSIONS: Dapagliflozin was similarly efficacious and safe in patients with HFrEF taking or not taking an MRA, supporting the use of both drugs together. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- *Heart Failure/drug therapy
- *Mineralocorticoid Receptor Antagonists/therapeutic use
- aldosterone
- Benzhydryl Compounds
- dapagliflozin
- Glucosides
- heart failure
- Humans
- hyperkalemia
- kidney function
- mineralocorticoid receptor antagonist
- potassium
- SGLT2 inhibitor
- Stroke Volume
- Ventricular Function
- Left
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Shen, Li
-
Kristensen, Sore ...
-
Bengtsson, Olof
-
Bohm, Michael
-
de Boer, Rudolf ...
-
Docherty, Kieran ...
-
show more...
-
Inzucchi, Silvio ...
-
Katova, Tzvetana
-
Kober, Lars
-
Kosiborod, Mikha ...
-
Langkilde, Anna ...
-
Lindholm, Daniel
-
Martinez, M. Fel ...
-
O’Meara, Eileen
-
Nicolau, Jose C.
-
Petrie, Mark C.
-
Ponikowski, Piot ...
-
Sabatine, Marc S ...
-
Schou, Morten
-
Sjostrand, Mikae ...
-
Solomon, Scott D ...
-
Jhund, Pardeep S ...
-
McMurray, John J ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
JACC. Heart fail ...
- By the university
-
Uppsala University